Trial Profile
Safety, Tolerability and Pharmacokinetics Study After Single and Multiple Oral Doses of Dabigatran Etexilate Capsule (110mg,150 mg b.i.d., 7 Days) in Healthy Chinese Subjects (Open Label Study)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Jun 2020
Price :
$35
*
At a glance
- Drugs Dabigatran etexilate (Primary)
- Indications Cardiomyopathies; Cardiovascular disorders; Deep vein thrombosis; Gastrointestinal haemorrhage; Pulmonary embolism; Stroke; Vascular disorders; Venous thromboembolism
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 30 May 2020 Results evaluating Pharmacokinetics and Safety of Dabigatran Etexilate after Single and Multiple Oral Doses in Healthy Chinese Subjects, published in the European Journal of Drug Metabolism and Pharmacokinetics
- 27 Jun 2014 New trial record